IQVIA Partners With Medera on Cardiac Gene Therapy Development
IQVIA partners with Medera to advance cardiac gene therapy programs for HFpEF, HFrEF, and DMD-associated cardiomyopathy with clinical operations...
Nurix Receives $10M Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader SAR448272
Sanofi initiates Phase 1 trial of STAT6 degrader SAR448272, triggering a $10M payment to Nurix under their ongoing collaboration.
SHY Therapeutics Doses First Patient in SHY-ONC6 Phase 1 Trial for Solid Tumors
SHY Therapeutics doses first patient in SHY-ONC6 Phase 1 trial, testing a novel proteasome inhibitor mechanism for solid tumors...
ORIC Launches Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer
ORIC Pharmaceuticals launches Himalayas-1, a 600-patient Phase 3 trial of rinzimetostat in metastatic prostate cancer, with results expected later...
RM-718 shows 11.6% BMI reduction in acquired hypothalamic obesity trial
RM-718 shows 11.6% BMI reduction in acquired hypothalamic obesity trial with reduced hyperpigmentation compared to earlier MC4R agonists.
Tonix Gets FDA Alignment on TNX-4800 Phase 2 Lyme Disease Study Design
Tonix gains FDA alignment on TNX-4800 Phase 2 study design for Lyme disease prevention using a long-acting monoclonal antibody...
Adlai Nortye Wins HREC Approval for AN4035 Pan-RAS ADC Phase I Trial
Adlai Nortye wins HREC approval for AN4035 Phase I Trial, a CEACAM5-targeting ADC with pan-RAS inhibitor payload entering human...
AXPAXLI Shows 72% Reduction in Injection Burden vs Aflibercept in Wet AMD
AXPAXLI reduces injection burden by 72% versus aflibercept in wet AMD, based on Phase 3 SOL-1 trial analysis.
Opus Genetics Completes Enrollment in OPGx-LCA5 Phase 3 Trial
Opus Genetics completes enrollment in OPGx-LCA5 Phase 3 trial for rare inherited retinal disease, with dosing starting Q4 2026.
Nurix Starts Phase 3 Trial of Bexobrutideg Against Pirtobrutinib in CLL
Nurix launches Phase 3 trial of bexobrutideg against pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia with dual primary endpoints.